Stewart Appelrouth Acquires 81,953 Shares of AIM ImmunoTech Inc. (NYSE:AIM) Stock

AIM ImmunoTech Inc. (NYSE:AIM) Director Stewart Appelrouth purchased 81,953 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were purchased at an average cost of $0.19 per share, with a total value of $15,571.07. Following the completion of the acquisition, the director now owns 321,752 shares in the company, valued at approximately $61,132.88. This represents a 34.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

AIM ImmunoTech Price Performance

NYSE AIM opened at $0.21 on Friday. The company’s fifty day moving average price is $0.26 and its two-hundred day moving average price is $0.33. AIM ImmunoTech Inc. has a 12 month low of $0.16 and a 12 month high of $0.62. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC bought a new position in AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on AIM shares. Ascendiant Capital Markets lowered their target price on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Maxim Group lowered their price objective on AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, October 22nd.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).